In the IDEAL trial, almost 9,000 patients with coronary heart disease were treated, after
randomisation, with atorvastatin, 80 mg daily, or simvastatin, 20 or 40 mg daily, for 4.8 years …

The Treating to New Targets (TNT) trial enrolled 10,001 patients with coronary disease to
treatment with atorvastatin, 80 or 10 mg/d, and observed them for a median of 4.9 years …

Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for
cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once …

Higher starting doses of atorvastatin may reduce LDL-cholesterol levels more than lower
doses. Commentary. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Familial hypercholesterolemia (FH) is a genetic disorder caused by a mutation affecting one
or both alleles encoding the LDL receptor. If left untreated, phenotype homozygotes usually …

Hypercholesterolemia is a major risk factor for the development of coronary heart disease.
HMG-CoA reductase inhibitors have been used as first-line drugs because of both their …

SUMMARY A total of 531 patients from 57 hospital centres across the UK, who had
previously been treated with lipid‐lowering agents in combination or alone, in whom the …

Results: The mean age of the 160 patients enrolled for the study was 58.95 Æ10. 22 (37 to
82). There was no difference between the groups with regards to demographic …

Synopsis Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …

A multicenter study was conducted to assess the efficacy of a generic form of Atorvastatin
(Ranbaxy's Storvas) in the treatment of Primary Hypercholesterolemia. One hundred and …